Presentations Eledon Corporate Presentation ASN Kidney Week 2023 Phase 1b Poster Eledon Pharmaceuticals Phase 1b Data Update Presentation ALS Phase 2a Clinical Trial Update Presentation Eledon Pharmaceuticals R&D Day Presentation Publications Tegoprubart for the treatment of patients with IgA nephropathy: a snapshot of emerging data from an ongoing trial Tegoprubart for the prevention of rejection in kidney transplant recipients: a snapshot of emerging data from an ongoing trial A Phase 2 Safety and Tolerability Study of an Anti CD40L Antibody, AT-1501 in Adults with ALS Pharmacokinetic and Toxicity Studies of an Anti-CD40L Antibody, AT-1501 in Rhesus Macaques The Development and Characterization of AT-1501, an Anti-CD40L Antibody Lacking Fc Effector Function
